Publications by authors named "Clotilde Simon"

Claim this Profile
P
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Jean-Yves Blay, Sylvie Chevret, Axel Le Cesne, Mehdi Brahmi, Nicolas Penel, Clotilde Simon

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gwenaelle Gravis, Patricia Marino, Daniel Olive, Frederique Penault-LLorca, Jean-Pierre Delord, Clotilde Simon

BMC Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Marie Véron, Sylvie Chevret, Jean-Jacques Grob, Marie Beylot-Barry, Philippe Saiag, Clotilde Simon

Eur J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Benoit Rousseau, Ivan Bieche, Eric Pasmant, Nadim Hamzaoui, Nicolas Leulliot, Clotilde Simon

Cancer Discov· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Clotilde Simon, Elisabetta Dondi, Amandine Chaix, Paulo de Sepulveda, Terrance J Kubiseski

Blood· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis